Organogenesis Holdings Inc reports results for the quarter ended March 31 - Earnings Summary

• Organogenesis Holdings Inc ORGO.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -2 cents. The mean expectation of four analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -9 cents to -3 cents per share.

• Revenue fell 21.2% to $86.69 million from a year ago; analysts expected $90.77 million.

• Organogenesis Holdings Inc's reported EPS for the quarter was a loss of 17 cents​.

• The company reported a quarterly loss of $21.59 million.

• Organogenesis Holdings Inc shares had risen by 19.9% this quarter and gained 61.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1,233.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Organogenesis Holdings Inc is $6.00

This summary was machine generated from LSEG data May 8 at 09:43 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)